Dabigatran etexilate mesylate

URI: https://gptkb.org/entity/Dabigatran_etexilate_mesylate
GPTKB entity
Statements (28)
Predicate Object
gptkbp:instanceOf gptkb:drug
gptkb:anticoagulant
gptkbp:activeIngredient gptkb:dabigatran
gptkbp:antidote gptkb:idarucizumab
gptkbp:approvalYear 2010
gptkbp:approvedBy gptkb:FDA
gptkbp:ATCCode B01AE07
gptkbp:CASNumber 211915-06-9
gptkbp:chemicalFormula C34H41N7O5·CH4O3S
gptkbp:contraindication severe renal impairment
gptkbp:developedBy gptkb:Boehringer_Ingelheim
gptkbp:eliminationHalfLife 12-17 hours
gptkbp:excretion gptkb:kidney
gptkbp:legalStatus prescription only
gptkbp:marketedAs gptkb:Pradaxa
gptkbp:mechanismOfAction gptkb:direct_thrombin_inhibitor
gptkbp:metabolism liver
gptkbp:molecularWeight 723.85 g/mol
gptkbp:pregnancyCategory C (US)
gptkbp:routeOfAdministration oral
gptkbp:sideEffect bleeding
gastrointestinal upset
gptkbp:usedFor prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis
treatment of pulmonary embolism
gptkbp:bfsParent gptkb:DB08890
gptkbp:bfsLayer 7
https://www.w3.org/2000/01/rdf-schema#label Dabigatran etexilate mesylate